UY32493A - " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones" - Google Patents

" (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones"

Info

Publication number
UY32493A
UY32493A UY0001032493A UY32493A UY32493A UY 32493 A UY32493 A UY 32493A UY 0001032493 A UY0001032493 A UY 0001032493A UY 32493 A UY32493 A UY 32493A UY 32493 A UY32493 A UY 32493A
Authority
UY
Uruguay
Prior art keywords
oxazolidin
isoxazol
pharmaceutically acceptable
acceptable salts
esters
Prior art date
Application number
UY0001032493A
Other languages
English (en)
Inventor
Kaveri Das
Radha Shandil
David Alan Melnick
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY32493A publication Critical patent/UY32493A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Abstract

(5R)-3-[4-[1-[2S)-2,3-dihidroxipropanoil]-3,6-dihidro-2H-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, o una de sus sales farmacéuticamente aceptables, o uno de sus ésteres hidrolizables in vivo, para usar en el tratamiento de Mycobacterium tuberculosis.
UY0001032493A 2009-03-16 2010-03-15 " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones" UY32493A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16038509P 2009-03-16 2009-03-16

Publications (1)

Publication Number Publication Date
UY32493A true UY32493A (es) 2010-10-29

Family

ID=42262301

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032493A UY32493A (es) 2009-03-16 2010-03-15 " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones"

Country Status (17)

Country Link
US (1) US20120035219A1 (es)
EP (1) EP2408452A1 (es)
JP (1) JP2012520864A (es)
KR (1) KR20110127219A (es)
CN (1) CN102355901A (es)
AR (1) AR075861A1 (es)
AU (1) AU2010224619A1 (es)
BR (1) BRPI1009510A2 (es)
CA (1) CA2755209A1 (es)
EA (1) EA201101328A1 (es)
IL (1) IL214715A0 (es)
MX (1) MX2011009263A (es)
SG (1) SG173770A1 (es)
TW (1) TW201036609A (es)
UY (1) UY32493A (es)
WO (1) WO2010106355A1 (es)
ZA (1) ZA201107562B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0103082A3 (en) * 1998-06-05 2002-12-28 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
WO2003084534A1 (en) * 2002-03-29 2003-10-16 Pharmacia & Upjohn Company Llc Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
WO2003099217A2 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
BRPI0620157A2 (pt) * 2005-12-15 2011-12-20 Activbiotics Pharma Llc usos de rifamicinas

Also Published As

Publication number Publication date
SG173770A1 (en) 2011-09-29
AU2010224619A1 (en) 2011-09-08
EP2408452A1 (en) 2012-01-25
CA2755209A1 (en) 2010-09-23
BRPI1009510A2 (pt) 2016-03-15
KR20110127219A (ko) 2011-11-24
US20120035219A1 (en) 2012-02-09
AR075861A1 (es) 2011-05-04
CN102355901A (zh) 2012-02-15
WO2010106355A1 (en) 2010-09-23
EA201101328A1 (ru) 2012-04-30
JP2012520864A (ja) 2012-09-10
IL214715A0 (en) 2011-11-30
MX2011009263A (es) 2011-09-15
TW201036609A (en) 2010-10-16
ZA201107562B (en) 2013-03-27

Similar Documents

Publication Publication Date Title
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
ES2523968T3 (es) Terapia de combinación antibacteriana para el tratamiento de infecciones por bacterias Gram-positivas
CR11532A (es) Formas cristalinas de dimetoxi-docetaxel y sus procedimientos de preparacion
DOP2011000249A (es) Compuesto de anillo fusionado y su uso
CL2015000829A1 (es) Inhibidores de histona desmetilasas
RS53124B (en) USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY
ES2721666T3 (es) Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo
BRPI0921022A2 (pt) tratamento com pirfenidona para pacientes com função hepática atípica
NZ604592A (en) Combinations comprising atypical antipsychotics and taar1 agonists
BR112015002183A2 (pt) processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma
ES2571998T3 (es) Composiciones y usos médicos de derivados del ajoeno
CL2012000640A1 (es) Uso del compuesto n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina o su sal para el tratamiento de cancer refractario a tratamiento con un agente anti-cancer.
CO6321240A2 (es) Compuestos de anillo fusionados como activadores de glucocinasa
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
CU20100063A7 (es) Benzotiazoles como moduladores del receptor de grelina
CL2011002649A1 (es) Uso de un aerosol que comprende levofloxacina u ofloxacina para preparar un medicamento util para el tratamiento de una infeccion bacteriana pulmonar.
CL2011002563A1 (es) Uso de nifuratel para tratar infecciones causadas por especies del género atopobium vaginae.
UY34856A (es) Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
BR112016024523A2 (pt) inibidor pde10 opticamente ativo
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.
CO6311076A2 (es) Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente
CO6680652A2 (es) Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina
CL2017001478A1 (es) Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr)
UY32493A (es) " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones"
AR092991A1 (es) Combinacion de un derivado de a 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de proteinquinasa activada por mitogenos (mek)

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190123